Bilophila wadsworthia (null)

Bilophila wadsworthia is a Gram-negative, obligately anaerobic, bile-resistant bacterium that is commonly found in the human gastrointestinal tract. It is notable for producing hydrogen sulfide through metabolism of taurine-conjugated bile acids, with distinctive rapid catalase activity. Bilophila species are occasionally implicated in clinical infections, including abscesses and appendicitis, and elevated abundance has been linked to gut inflammation and metabolic derangements. While not a molecular target, Bilophila can be therapeutically targeted by antibiotics such as imipenem, cefoxitin, and ticarcillin, and its population may be reduced through dietary interventions (e.g., prebiotics like inulin)[1][3][4][5][6][2].

Other names

BilophilaBilophila wadsworthiaB. wadsworthia

β-lactam antibiotics: Inhibition of bacterial cell wall synthesis (drugs like imipenem, cefoxitin, ticarcillin; Bilophila strains may be resistant to standard penicillins due to β-lactamase production)[5] Prebiotics: i.e., inulin, can reduce Bilophila wadsworthia populations via modulation of gut microbiome (not a direct molecular mechanism)[4]